Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2012
07/19/2012US20120184569 A3 adenosine receptor agonists and antagonists
07/19/2012US20120184566 Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
07/19/2012US20120184565 Compounds for the reduction of beta-amyloid production
07/19/2012US20120184563 Composition for external application comprising aripiprazole and organic acid as active ingredients
07/19/2012US20120184562 1,6- and 1,8-naphthyridines
07/19/2012US20120184557 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof
07/19/2012US20120184556 Substituted enzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators
07/19/2012US20120184554 Therapeutic agent for mood disorders
07/19/2012US20120184553 Novel compounds
07/19/2012US20120184550 Substituted nicotinamides as kcnq2/3 modulators
07/19/2012US20120184548 Carboxylic acid aryl amides
07/19/2012US20120184547 Methods for treating schizophrenia
07/19/2012US20120184542 Pyrido pyrimidines
07/19/2012US20120184540 1,4 oxazines as bace1 and/or bace2 inhibitors
07/19/2012US20120184539 Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
07/19/2012US20120184538 Isoxazolo-pyridine derivatives
07/19/2012US20120184537 [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
07/19/2012US20120184535 Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
07/19/2012US20120184534 Tri-cyclic pyrazolopyridine kinase inhibitors
07/19/2012US20120184533 Small molecule inhibitors of parp activity
07/19/2012US20120184532 Galantamine amino acid and peptide prodrugs and uses thereof
07/19/2012US20120184531 BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA
07/19/2012US20120184528 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
07/19/2012US20120184527 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
07/19/2012US20120184525 1,2,3-triazolo [4,3-a] pyridine derivatives and thier use for the treatment of prevention of neurological and psychiatric disorders
07/19/2012US20120184524 Pyrazolopyridine kinase inhibitors
07/19/2012US20120184523 C-Met Modulators and Method of Use
07/19/2012US20120184520 Glycine compound
07/19/2012US20120184518 Methods of treating or preventing an inflammatory disease or condition using glutaminyl cyclase inhibitors
07/19/2012US20120184496 Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
07/19/2012US20120184492 Therapeutic use of a growth factor, nsg33
07/19/2012US20120184484 Lactoferrin and brain health and development in infants
07/19/2012US20120184483 Lactoferrin and neuronal health and development in the infant gut
07/19/2012US20120184482 Novel Ubiquitin-Isopeptide Probes
07/19/2012US20120184480 Use of constrained dipeptide and tripeptide mimic oligomers as vectorization agents
07/19/2012US20120183635 Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses
07/19/2012US20120183620 mesoporous drug delivery system using an electrically conductive polymer
07/19/2012US20120183612 Matrix for sustained, invariant and independent release of active compounds
07/19/2012US20120183610 glucocorticoid therapy
07/19/2012US20120183599 Pharmaceutical Composition
07/19/2012US20120183583 Medical Device With Intrapore Films
07/19/2012US20120183579 Compounds for inflammation and immune-related uses
07/19/2012US20120183565 Fully human antibodies to btla
07/19/2012US20120183564 Inhibition of endosomal toll-like receptor activation
07/19/2012US20120183563 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
07/19/2012US20120183560 Monoclonal Antibodies
07/19/2012US20120183558 Antibody molecules which bind il-17a and il-17f
07/19/2012US20120183542 Treating neurological disorders
07/19/2012US20120183527 Measurement of anti-amyloid antibodies in human blood
07/19/2012US20120183522 Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
07/19/2012US20120183520 Minimally invasive methods for treating dysfunction of cardiac muscle
07/19/2012US20120183511 Induction of neuronal differentiation in non-neuronal cells using a nucleic acid molecule
07/19/2012US20120183510 High-throughput culture and transfer device and method
07/19/2012US20120183498 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
07/19/2012CA2824220A1 Novel heterocyclic derivatives and their use in the treatment of neurological disorders
07/19/2012CA2824207A1 Crystalline oxazine derivative and its use as bace inhibitor
07/19/2012CA2824097A1 Oxazine derivatives and their use in the treatment of neurological disorders
07/19/2012CA2824050A1 Methods and drug products for treating alzheimer's disease
07/19/2012CA2824047A1 Heteroaryl compounds and methods of use thereof
07/19/2012CA2823126A1 Tofu for smoking abstention
07/19/2012CA2814763A1 Compositions comprising enzyme-cleavable oxycodone prodrug
07/18/2012EP2476682A1 8-oxodihydropurine derivative
07/18/2012EP2476681A2 Amino-aza-adamantane derivatives and methods of use
07/18/2012EP2476680A1 (1-Azinone)-Substituted Pyridoindoles
07/18/2012EP2476671A1 1H-Quinazoline-2,4-diones
07/18/2012EP2476414A1 Transdermally absorbable preparation
07/18/2012EP2475665A1 [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS
07/18/2012EP2475664A2 Histamine h3 inverse agonists and antagonists and methods of use thereof
07/18/2012EP2475663A2 Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities
07/18/2012EP2475662A2 Histamine h3 inverse agonists and antagonists and methods of use thereof
07/18/2012EP2475429A1 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
07/18/2012EP2475428A1 Heterocylcic derivatives as inhibitors of glutaminyl cyclase
07/18/2012EP2283022B1 Furo [3, 2-b]pyrr0l-3-0nes as cathepsin s inhibitors
07/18/2012EP2216039B1 Pharmaceutical compositions for treating anxiety
07/18/2012EP2101763B1 Pharmaceutical compositions and their methods of use
07/18/2012EP1669065B1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient
07/18/2012EP1608648B1 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
07/18/2012EP1437961B1 Methods of suppressing microglial activation
07/18/2012CN202336063U 一种软胶囊 A soft capsule
07/18/2012CN1935260B Human antibodies that bind human tnfalpha
07/18/2012CN1443167B Azacyclic compounds for use in treatment of 5-serotonin related diseases
07/18/2012CN1440408B Inhibitors of human phosphatidyl-inositol 3-kinase delta
07/18/2012CN102597234A Humanized anti-amyloid-beta oligomer antibody
07/18/2012CN102597233A Humanized anti-amyloid-beta oligomer antibody
07/18/2012CN102596999A Antibody recognizing turn structure in amyloid beta
07/18/2012CN102596997A Antibodies that specifically bind to A beta oligomers and use thereof
07/18/2012CN102596965A Pyrrolo [3,2-E] [1,2,4] triazolo [1,5-A] pyrimidines derivatives as inhibitors of microglia activation
07/18/2012CN102596964A Pyrrolo [3,2-E] [1,2,4] triazolo [1,5-A] pyrimidines derivatives as inhibitors of microglia activation
07/18/2012CN102596961A Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
07/18/2012CN102596955A Histamine H3 inverse agonists and antagonists and methods of use thereof
07/18/2012CN102596949A 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
07/18/2012CN102596942A Cyclic triazo sodium channel blockers
07/18/2012CN102596938A Alkyl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596934A Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596921A Novel compounds
07/18/2012CN102596918A Aryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596905A 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
07/18/2012CN102596904A Protease inhibitors, compositions and methods of use
07/18/2012CN102596322A Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
07/18/2012CN102596225A Use of a neuregulin to treat peripheral nerve injury
1 ... 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 ... 1833